Navigation Links
Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Date:9/10/2007

ete

resolution of lung metastases by CT/PET with significant improvement in

dypsnea (shortness of breath);

-- 1 patient (11 prior regimens, 5 with trastuzumab, 2 with lapatinib)

showed 10% reduction in tumor mass with change consistent with tumor

necrosis and a decrease in 2 tumor markers (64% CEA, 63% CA27.29);

-- 1 patient (5 prior regimens) showed a partial response after 2 cycles,

confirmed after 4 cycles, with 52% decrease hepatic lesions);

-- 5 patients had extended stable disease (4, 6+, 6+, 8 and 10 months).

Of the 3 patients with ovarian cancer,

-- 1 patient (13 prior regimens) who was on study for more than 19 months

with evaluable disease had a near complete resolution of ascites and

left pleural effusion at the end of cycle 2, and an 83%

decrease in CA125.

Toxicities were mainly Grade 1 and 2 (diarrhea, fatigue, headache, arthralgia, nausea). One patient with multiple prior trastuzumab and doxorubicin containing regimens experienced a dose-limiting toxicity of shortness of breath and left ventricular ejection fraction reduction at 100 mg/m2. Two patients treated at 80 mg/m2 experienced reversible Grade 3 ocular keratitis; following a treatment holiday both patients continued therapy with reduced doses (one patient remains on study). Kosan plans to continue to enroll patients at the 80 mg/m2 for further safety and efficacy evaluation.

Expanded Phase 1 Trial Includes Paclitaxel

Kosan has expanded the Phase 1 trial to add weekly dosing with paclitaxel (Taxol (R)). In this triplet combination regimen, patients will continue to receive trastuzumab at full dose on a continuous weekly schedule. Alvespimycin will be dosed weekly for 3 weeks out of 4, and paclitaxel will be given on the same schedule.

Alvespimycin Development Plan

In the fourth quarter of 2007, Kosan plans to initiate a Phase 2 trial of alvespimycin as monotherapy
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
6. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
7. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
8. ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)...  Mylan Inc. (NASDAQ: MYL ) today announced ... Abbott (NYSE: ABT ) whereby ... markets specialty and branded generics business ("the Assets") in an ... receive 105 million shares of the combined company worth approximately ... Friday, July 11, 2014, representing an approximately 21% ownership stake. ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "Global Hypodermic Needles Market 2014-2018" report to ... A hypodermic needle is a hollow needle ... the body or or to extract fluids from it. ... liquids or to inject substances that cannot be ingested. ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... International Myeloma Workshop held in,Kos, Greece ... with bortezomib, dexamethasone and lenalidomide plus,dexamethasone, ... as a single agent in patients ... 29, 2007 /PRNewswire-FirstCall/ -- Keryx,Biopharmaceuticals, Inc. ...
... 2007--A cervical cancer vaccine has shown 90%,efficacy for prevention ... papillomavirus (HPV) types targeted by,the vaccine, conclude authors of ... of The Lancet., HPV types 16 and 18 account ... there are up to 15,oncogenic HPV types which can ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7Vaccine Can Prevent Cervical Cancer and Precancerous Lesions 2
(Date:7/14/2014)... 14, 2014 According to the Boost Your Bust ... for women who want to learn how to increase the size ... consists of 7 chapters including:, , Chapter 1 ... Chapter 2 – How Natural Breast Enlargement Works , ... Look Bigger , Chapter 4 – The Groundwork , ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 In ... carriers emphasized lower-cost narrow-network products, accountable care organizations ... chose coverage based on price, rather than on ... from seeking care from out-of-network providers. “Using ... Narrow Networks and Exchange Products,” the July ...
(Date:7/14/2014)... EnergyFirst, manufacturer of all-natural ... Permalean for its great products, thriving customer base, ... markets its products as Jim’s Permalean Protein Powders and ... EnergyFirst’s lineup of nutritional products. The Permalean brand ... year. , Founded in 1999, Permalean’s products were designed ...
(Date:7/14/2014)... CA (PRWEB) July 14, 2014 Crystal ... new office in Sacramento. The announcement has been made via ... office. In addition, the announcement has been made in order ... dental services in the Sacramento area. , Crystal Dental offers ... Some of the services offered by Crystal Dental include cosmetic ...
(Date:7/13/2014)... The special two-day sale starts today on the fan-favorite ... code 20SCRUB at the webstore checkout. The sale expires midnight ... Citrus Scrub falls in love with it," says Sublime ... cleanser for face, but can also be used on the ... exfoliate with pleasure, clean pores and wash away dead skin ...
Breaking Medicine News(10 mins):Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Milliman, FAIR Health Executives to Discuss Data-Based Rate Setting for Out-of-Network Providers in Atlantic Information Services Webinar 2Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 2Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 3Health News:Crystal Dental Announces the Opening of New Office Location in Sacramento 2Health News:Discover the Favorite Sublime Beauty® Citrus Scrub: Special "Two-Day Only" Sale 2
... may be more prone to an alcohol-induced headache after ... Jefferson Headache Center. The research will be presented at ... Neuroscience, in Chicago. Until now, studying the mechanism ... not been possible in an animal model, according to ...
... Macrophages, the scavenger cells of the body,s immune ... University School of Medicine researchers have identified one pathway ... causes a lupuslike autoimmune disease. The findings could ... of lupus in humans and potential drug treatments for ...
... e cigarettes sales have generally been tobacco smoking individuals ... online sales associate for E-Cigarettes National, reports an influx ... loved ones that smoke. "Some of these callers are ... starter kit for their spouses or partners that have ...
... is important to many who undergo weight-reduction surgery, study finds ... obese -- a step above overweight -- by the age ... polycystic ovarian syndrome than others, new research suggests. , ... than women who become obese when they,re older, according to ...
... cookie diets recently featured in the media have been criticized ... Smart for Life Cookie Diet should not be grouped in ... that are all-natural, 60% organic, and filled with nutrients and ... that has become much more than a simple cookie diet ...
... open enrollment season, and millions of employees are focusing ... a serious health issue strikes, it isn,t enough to ... on making sure you,re prepared to weather the storm ... this report from Guardian at: http://inr.mediaseed.tv/oneClip_C/?feed=BJ5vKAI3hMPsemBun4FIM6cBCcDeE0bZ ...
Cached Medicine News:Health News:Migraine sufferers more prone to hangover headache 2Health News:Stanford study identifies cellular mechanism that causes lupuslike symptoms in mice 2Health News:Stanford study identifies cellular mechanism that causes lupuslike symptoms in mice 3Health News:Online Sales of E Cigarettes Expected to Rise Over the Holidays 2Health News:Obesity May Affect Fertility in Young Women 2Health News:Smart for Life(TM) Cookie Diet Provides Nutrients 2Health News:Smart for Life(TM) Cookie Diet Provides Nutrients 3
OKN drum...
Accurately tests for Nystagmus when rotated at 8-10 rpm. Drums are 10" high by 8" diameter. Light weight drum of professional quality with ball bearings for effortless spin mechanism. For use 24 to 3...
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
The rectangular large-field lens of the 2631 are ideal for reading and writing....
Medicine Products: